Digest Network Come funziona
Network
/
Società
Cy
Non verificato

Cycle Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
03/02/2026
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
Mercato azionario
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
28/01/2026
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
16/10/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Industria
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
21/07/2025
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
17/07/2025
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Industria
Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
19/06/2025
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
22/04/2025
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Cycle Pharmaceuticals Launches Cycle Vita PKU™, an AI-Powered Smartphone App for On-The-Go Management of Phenylketonuria (PKU)
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0
14/10/2024
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Fonte
Cycle Pharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0